N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2h-1,4-benzoxa zin-7-yl)acetamide derivatives and related compounds as ror-gamma modulators for treating autoimmune diseases
US-2019365768-A1 · Dec 5, 2019 · US
Oncotherapeutic application of inhibitors of high-affinity glucose transporters
US8999326B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8999326-B2 |
| Application number | US-67367708-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 15, 2008 |
| Priority date | Aug 17, 2007 |
| Publication date | Apr 7, 2015 |
| Grant date | Apr 7, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The subject invention concerns materials and methods for treating oncological disorders in a person or animal using any agent or compound that inhibits uptake of glucose into a cell. The subject invention also concerns methods for inducing apoptosis and inhibiting the proliferation or survival of a cell. In one embodiment, the methods comprise administering an effective amount of an agent or compound that inhibits the activity of one or more glucose transporter proteins, such as Glut-1. An antibody that binds to and inhibits a glucose transporter protein can be used in the present methods.
First claim
Opening claim text (preview).
I claim: 1. A method for treating a person or animal, said method comprising administering an antibody, or antigen binding fragment thereof, that binds to glucose transporter-1 (Glut-1) protein, wherein the person or animal has breast or lung cancer. 2. The method according to claim 1 , wherein said antibody or antigen binding fragment is administered prior to, subsequent to, or in combination with an anticancer agent, and/or with radiation therapy, and/or with…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8999326B2 cover?
- The subject invention concerns materials and methods for treating oncological disorders in a person or animal using any agent or compound that inhibits uptake of glucose into a cell. The subject invention also concerns methods for inducing apoptosis and inhibiting the proliferation or survival of a cell. In one embodiment, the methods comprise administering an effective amount of an agent or co…
- Who is the assignee on this patent?
- Simon George R, Univ South Florida
- What technology area does this patent fall under?
- Primary CPC classification A61K31/39. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).